retatrutide type 2 diabetes 🩺 in diabetes: TRANSCEND-T2D-1 Phase 3 results → HbA1c ↓2.0% + weight ↓16.8% at 40 weeks. A triple agonist that tackles both glycemia and obesity simultaneously. 📊💊 Ref: Lilly retatrutide type 2 diabetes phase

Key Takeaways GLP-1 medications can reduce appetite and food intake, which may make it harder to meet daily nutrient needs during weight loss

PMID 17622601

Who are Ros weight loss offerings for

It is one of the factors that could affect the FDAs review timeline

If you want a more detailed comparison of how tirzepatide stacks up against other GLP-1 medications , the timing principles remain largely the same across the class, but side effect profiles differ enough to warrant individual testing

Neuroprotective and Neurotrophic Actions of Glucagon-Like Peptide-1: An Emerging Opportunity to Treat Neurodegenerative and Cerebrovascular Disorders